Loading clinical trials...
Loading clinical trials...
A Multicenter Phase 1/2 Study of Venetoclax/Daratumumab/Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis With Translocation (11;14)
Conditions
Interventions
Venetoclax
Dexamethasone
+2 more
Start Date
January 8, 2024
Primary Completion Date
December 31, 2028
Completion Date
December 31, 2028
Last Updated
March 6, 2025
NCT06383143
NCT06192979
NCT07250269
NCT06022939
NCT04839003
NCT05066607
Lead Sponsor
Alfred Chung, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions